Climb Bio updates on budoprutug and CLYM116 trials; cash runway into 2028

Climb Bio, Inc.

First patient dosed in PrisMN Phase 2 trial of budoprutug for primary membranous nephropathy (Nov 2025).
Received China IND clearance for budoprutug in SLE; parallel China Phase 1b to enroll lupus nephritis patients (Dec 2025).
Completed dosing of first cohort in Phase 1 trial of subcutaneous budoprutug and of CLYM116 in healthy volunteers (Dec 2025).
Expects initial data from SC budoprutug Phase 1 (H1 2026), budoprutug pMN Phase 2 (H2 2026), and CLYM116 Phase 1 (mid-2026).
Cash, cash equivalents, and marketable securities expected to fund operations into 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.